Medpace Holdings Beheer

Beheer criteriumcontroles 4/4

De CEO Medpace Holdings is August Troendle, benoemd in Jul1992, heeft een ambtstermijn van 32.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.65M, bestaande uit 49.5% salaris en 50.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 17.37% van de aandelen van het bedrijf, ter waarde € 1.73B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 6.3 jaar.

Belangrijke informatie

August Troendle

Algemeen directeur

US$1.6m

Totale compensatie

Percentage CEO-salaris	49.5%
Dienstverband CEO	32.3yrs
Eigendom CEO	17.4%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is August Troendle's beloning veranderd ten opzichte van Medpace Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$366m
Jun 30 2024	n/a	n/a	US$340m
Mar 31 2024	n/a	n/a	US$312m
Dec 31 2023	US$2m	US$814k	US$283m
Sep 30 2023	n/a	n/a	US$273m
Jun 30 2023	n/a	n/a	US$268m
Mar 31 2023	n/a	n/a	US$257m
Dec 31 2022	US$2m	US$770k	US$245m
Sep 30 2022	n/a	n/a	US$227m
Jun 30 2022	n/a	n/a	US$209m
Mar 31 2022	n/a	n/a	US$199m
Dec 31 2021	US$6m	US$697k	US$181m
Sep 30 2021	n/a	n/a	US$182m
Jun 30 2021	n/a	n/a	US$175m
Mar 31 2021	n/a	n/a	US$159m
Dec 31 2020	US$4m	US$608k	US$145m
Sep 30 2020	n/a	n/a	US$124m
Jun 30 2020	n/a	n/a	US$107m
Mar 31 2020	n/a	n/a	US$110m
Dec 31 2019	US$8m	US$504k	US$100m
Sep 30 2019	n/a	n/a	US$93m
Jun 30 2019	n/a	n/a	US$88m
Mar 31 2019	n/a	n/a	US$78m
Dec 31 2018	US$528k	US$420k	US$73m
Sep 30 2018	n/a	n/a	US$61m
Jun 30 2018	n/a	n/a	US$52m
Mar 31 2018	n/a	n/a	US$45m
Dec 31 2017	US$598k	US$419k	US$39m

Compensatie versus markt: De totale vergoeding ($USD 1.65M ) August } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.78M ).

Compensatie versus inkomsten: De vergoeding van August is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

August Troendle (68 yo)

32.3yrs

Tenure

US$1,646,031

Compensatie

Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
August Troendle	Chairman & CEO	32.3yrs	US$1.65m	17.37% € 1.7b
Jesse Geiger	President	3.3yrs	US$945.08k	0.069% € 6.9m
Kevin Brady	CFO & Treasurer	5.8yrs	US$690.48k	0.019% € 1.9m
Susan Burwig	Executive Vice President of Operations	7.8yrs	US$1.12m	0.21% € 20.9m
Stephen Ewald	Chief Compliance Officer	12.4yrs	US$914.64k	0.043% € 4.3m
Brandon Ebken	Chief Information Officer	3.8yrs	geen gegevens	geen gegevens
Lauren Morris	Associate Director of Investors Relations	no data	geen gegevens	geen gegevens
Todd Meyers	Vice President of Business Development & Marketing	no data	geen gegevens	geen gegevens
John Wynne	Senior Vice President of Commercial Operations & Clinical Pharmacology Unit	no data	geen gegevens	geen gegevens
Reinilde Heyrman	Chief Medical Officer of Medical Department	1.8yrs	geen gegevens	geen gegevens
Gina Leisring	Senior Vice President of Clinical Monitoring	no data	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 01P is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
August Troendle	Chairman & CEO	32.3yrs	US$1.65m	17.37% € 1.7b
Fred Davenport	Lead Independent Director	6.3yrs	US$264.98k	0.0065% € 643.7k
Cornelius McCarthy	Independent Director	6.3yrs	US$217.48k	0.017% € 1.7m
Robert Kraft	Independent Director	8.3yrs	US$227.35k	0.0019% € 190.6k
Brian Carley	Independent Director	8.3yrs	US$234.97k	0.070% € 7.0m
Femida Gwadry-Sridhar	Independent Director	1.8yrs	US$258.37k	0% € 0
Dani Zander	Director	less than a year	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 01P wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Medpace Holdings Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Executive Vice President of Operations recently sold €2.8m worth of stock

Chairman & CEO recently sold €3.5m worth of stock

Chairman & CEO recently sold €6.3m worth of stock

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Chairman & CEO recently sold €23m worth of stock

Executive Vice President of Operations recently sold €3.5m worth of stock

Recent updates

Investor sentiment improves as stock rises 16%

Third quarter 2024 earnings released: EPS: US$3.11 (vs US$2.30 in 3Q 2023)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024

Executive Vice President of Operations recently sold €2.8m worth of stock

Chairman & CEO recently sold €3.5m worth of stock

Chairman & CEO recently sold €6.3m worth of stock

New minor risk - Share price stability

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023)

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024

Chairman & CEO recently sold €23m worth of stock

Investor sentiment improves as stock rises 18%

Full year 2023 earnings released: EPS: US$9.21 (vs US$7.57 in FY 2022)

Executive Vice President of Operations recently sold €3.5m worth of stock

Now 21% undervalued

Chairman & CEO recently sold €20m worth of stock

Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$2.30 (vs US$2.13 in 3Q 2022)

Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023

Now 20% undervalued

Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023

Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive Index

Now 21% undervalued

First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$7.58 (vs US$5.06 in FY 2021)

Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board

CFO & Treasurer recently sold €440k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021)

Medpace Holdings, Inc. (NasdaqGS:MEDP) announces an Equity Buyback for $500 million worth of its shares.

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2022 and 2023

Medpace Holdings, Inc. to Report Q3, 2022 Results on Oct 24, 2022

Chairman & CEO recently bought €15m worth of stock

Chairman & CEO recently bought €10m worth of stock

Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc. to Report Q2, 2022 Results on Jul 25, 2022

Insufficient new directors

First quarter 2022 earnings released: EPS: US$1.76 (vs US$1.21 in 1Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc., Annual General Meeting, May 20, 2022

Investor sentiment improved over the past week

Lead Independent Director recently bought €64k worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medpace Holdings, Inc. Provides Consolidated Earnings Guidance for the Year 2022

Now 22% undervalued after recent price drop

Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020)

First quarter 2021 earnings released: EPS US$1.21 (vs US$0.80 in 1Q 2020)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021

Medpace Holdings, Inc. to Report Q1, 2021 Results on Apr 26, 2021

Executive Vice President of Operations recently sold €859k worth of stock

Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019)

Revenue beats expectations

New 90-day high: €121

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index

Medpace Holdings, Inc. to Report Q4, 2020 Results on Feb 15, 2021